Literature DB >> 10361880

Pharmacology and cardiovascular implications of the kinin-kallikrein system.

A Dendorfer1, S Wolfrum, P Dominiak.   

Abstract

Kinins are peptide hormones that can exert a significant influence on the regulation of blood pressure and vascular tone due to their vasodilatatory, natriuretic and growth modulating activity. Their cardiovascular involvement in physiological and pathophysiological situations has been studied intensively since inhibitors for angiotensin I-converting enzyme and selective receptor antagonists have become available for pharmacologically potentiating or inhibiting kinin-mediated reactions. Molecular biological analysis and the establishment of genetically modified animal models have also allowed newer information to be acquired on this subject. In this review, the components and cardiovascularly relevant mechanisms of the kinin-kallikrein system shall be described. Organ-specific effects concerning the kidneys, the vascular system, the heart and nervous tissue shall also be illustrated. On this issue, the physiological functions and pathophysiological implications of the kinin-kallikrein system should be clearly distinguished from the many, mostly endothelium-mediated protective effects which occur during ACE inhibition due to the potentiation of kinin effects. Finally, a view shall also be cast upon newly discovered targets of action, which could be exploited for therapeutically altering the kinin-kallikrein system.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10361880     DOI: 10.1254/jjp.79.403

Source DB:  PubMed          Journal:  Jpn J Pharmacol        ISSN: 0021-5198


  9 in total

1.  Metabolites as novel biomarkers for childhood obesity-related traits in Mexican-American children.

Authors:  V S Farook; L Reddivari; G Chittoor; S Puppala; R Arya; S P Fowler; K J Hunt; J E Curran; A G Comuzzie; D M Lehman; C P Jenkinson; J L Lynch; R A DeFronzo; J Blangero; D E Hale; R Duggirala; J Vanamala
Journal:  Pediatr Obes       Date:  2014-11-18       Impact factor: 4.000

2.  Non-competitive pharmacological antagonism at the rabbit B(1) receptor.

Authors:  J F Larrivée; L Gera; S Houle; J Bouthillier; D R Bachvarov; J M Stewart; F Marceau
Journal:  Br J Pharmacol       Date:  2000-11       Impact factor: 8.739

3.  Apstatin, a selective inhibitor of aminopeptidase P, reduces myocardial infarct size by a kinin-dependent pathway.

Authors:  S Wolfrum; G Richardt; P Dominiak; H A Katus; A Dendorfer
Journal:  Br J Pharmacol       Date:  2001-09       Impact factor: 8.739

4.  Effect of Montelukast on bradykinin-induced contraction of isolated tracheal smooth muscle of guinea pig.

Authors:  A Noor; M H Najmi; S Bukhtiar
Journal:  Indian J Pharmacol       Date:  2011-07       Impact factor: 1.200

Review 5.  A Novel Category of Anti-Hypertensive Drugs for Treating Salt-Sensitive Hypertension on the Basis of a New Development Concept.

Authors:  Makoto Katori; Masataka Majima
Journal:  Pharmaceuticals (Basel)       Date:  2010-01-07

Review 6.  The modular nature of bradykinin-potentiating peptides isolated from snake venoms.

Authors:  Juliana Mozer Sciani; Daniel Carvalho Pimenta
Journal:  J Venom Anim Toxins Incl Trop Dis       Date:  2017-10-26

7.  Cryo-EM structures of human bradykinin receptor-Gq proteins complexes.

Authors:  Jinkang Shen; Dongqi Zhang; Yao Fu; Anqi Chen; Xiaoli Yang; Haitao Zhang
Journal:  Nat Commun       Date:  2022-02-07       Impact factor: 17.694

8.  Bradykinin-Potentiating Activity of a Gamma-Irradiated Bioactive Fraction Isolated from Scorpion (Leiurus quinquestriatus) Venom in Rats with Doxorubicin-Induced Acute Cardiotoxicity: Favorable Modulation of Oxidative Stress and Inflammatory, Fibrogenic and Apoptotic Pathways.

Authors:  Lamiaa A Ahmed; Fatma Y Abdou; Abir A El Fiky; Esmat A Shaaban; Afaf A Ain-Shoka
Journal:  Cardiovasc Toxicol       Date:  2020-08-29       Impact factor: 3.231

9.  KLK1 and ZG16B proteins and arginine-proline metabolism identified as novel targets to monitor atherosclerosis, acute coronary syndrome and recovery.

Authors:  Marta Martin-Lorenzo; Irene Zubiri; Aroa S Maroto; Laura Gonzalez-Calero; Maria Posada-Ayala; Fernando de la Cuesta; Laura Mourino-Alvarez; Luis F Lopez-Almodovar; Eva Calvo-Bonacho; Luis M Ruilope; Luis R Padial; Maria G Barderas; Fernando Vivanco; Gloria Alvarez-Llamas
Journal:  Metabolomics       Date:  2014-12-14       Impact factor: 4.290

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.